Protara Therapeutics, Inc.
TARA
$3.11
$0.010.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -50.86M | -45.42M | -44.60M | -42.05M | -40.69M |
| Total Depreciation and Amortization | 347.00K | 332.00K | 332.00K | 357.00K | 352.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.47M | 3.98M | 4.45M | 5.21M | 5.70M |
| Change in Net Operating Assets | 2.34M | 966.00K | 4.01M | 1.29M | 1.31M |
| Cash from Operations | -44.71M | -40.14M | -35.81M | -35.20M | -33.33M |
| Capital Expenditure | -74.00K | -107.00K | -63.00K | -63.00K | -92.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -112.89M | -62.19M | 19.22M | 11.24M | 47.03M |
| Cash from Investing | -112.97M | -62.30M | 19.16M | 11.17M | 46.94M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 151.44M | 151.56M | 149.03M | 45.13M | 135.00K |
| Repurchase of Common Stock | -185.00K | -192.00K | -83.00K | -83.00K | -110.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -51.66M | -9.70M | -9.09M | -3.03M | 41.96M |
| Cash from Financing | 99.59M | 141.67M | 139.87M | 42.02M | 41.99M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -58.09M | 39.23M | 123.21M | 17.99M | 55.60M |